Chromatin modifiers and the promise of epigenetic therapy in acute leukemia

Leukemia

Volumn 28, Issue 7, 2014, Pages 1396-1406

  Greenblatt, S M ^a   Nimer, S D ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; DNA METHYLTRANSFERASE INHIBITOR; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE INHIBITOR; ISOCITRATE DEHYDROGENASE 1; METHYLTRANSFERASE; MIXED LINEAGE LEUKEMIA PROTEIN; POLYCOMB GROUP PROTEIN; PROTEIN ARGININE METHYLTRANSFERASE; RETINOIC ACID; TET2 PROTEIN; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMATIN; CHROMATIN STRUCTURE; EPIGENETICS; GENE MUTATION; HUMAN; LEUKEMOGENESIS; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; REVIEW; SOMATIC MUTATION;

ACUTE DISEASE; ANTINEOPLASTIC AGENTS; CHROMATIN; EPIGENESIS, GENETIC; HUMANS; LEUKEMIA; MUTATION; PROGNOSIS;

EID: 84904070819     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.94     Document Type: Review

References (164)

1. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013 368 2059-2074.
2. Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012 481 157-163.
3. Tadokoro Y, Ema H, Okano M, Li E, Nakauchi H. De novo DNA methyltransferase is essential for self-renewal, but not for differentiation, in hematopoietic stem cells. J Exp Med 2007 204 715-722.
4. Broske AM, Vockentanz L, Kharazi S, Huska MR, Mancini E, Scheller M et al. DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction. Nat Genet 2009 41 1207-1215.
5. Bock C, Beerman I, Lien WH, Smith ZD, Gu H, Boyle P et al. DNA methylation dynamics during in vivo differentiation of blood and skin stem cells. Mol Cell 2012 47 633-647.
6. Ji H, Ehrlich LI, Seita J, Murakami P, Doi A, Lindau P et al. Comprehensive methylome map of lineage commitment from haematopoietic progenitors. Nature 2010 467 338-342.
7. Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 2010 17 13-27.
8. Deneberg S, Guardiola P, Lennartsson A, Qu Y, Gaidzik V, Blanchet O et al. Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks. Blood 2011 118 5573-5582.
9. Figueroa ME, Chen SC, Andersson AK, Phillips LA, Li Y, Sotzen J et al. Integrated genetic and epigenetic analysis of childhood acute lymphoblastic leukemia. J Clin Investig 2013 123 3099-3111.
10. Lugthart S, van Drunen E, van Norden Y, van Hoven A, Erpelinck CA, Valk PJ et al. High EVI1 levels predict adverse outcome in acute myeloid leukemia prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood 2008 111 4329-4337.
11. Lugthart S, Figueroa ME, Bindels E, Skrabanek L, Valk PJ, Li Y et al. Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. Blood 2011 117 234-241.
12. Jiang Y, Dunbar A, Gondek LP, Mohan S, Rataul M, O'Keefe C et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009 113 1315-1325.
13. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010 363 2424-2433.
14. Thol F, Damm F, Ludeking A, Winschel C, Wagner K, Morgan M et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol 2011 29 2889-2896.
15. Marcucci G, Metzeler KH, Schwind S, Becker H, Maharry K, Mrozek K et al. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol 2012 30 742-750.
16. Grossmann V, Haferlach C, Weissmann S, Roller A, Schindela S, Poetzinger F et al. The molecular profile of adult T-cell acute lymphoblastic leukemia mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL. Genes Chromosomes Cancer 2013 52 410-422.
17. Neumann M, Heesch S, Schlee C, Schwartz S, Gokbuget N, Hoelzer D et al. Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations. Blood 2013 121 4749-4752.
18. Yan XJ, Xu J, Gu ZH, Pan CM, Lu G, Shen Y et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 2011 43 309-315.
19. Kim SJ, Zhao H, Hardikar S, Singh AK, Goodell MA, Chen T. A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells. Blood 2013 122 4086-4089.
20. Challen GA, Sun D, Jeong M, Luo M, Jelinek J, Berg JS et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet 2012 44 23-31.
21. Trowbridge JJ, Sinha AU, Zhu N, Li M, Armstrong SA, Orkin SH. Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains. Gene Dev 2012 26 344-349.
22. Ito S, D'Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010 466 1129-1133.
23. Pastor WA, Pape UJ, Huang Y, Henderson HR, Lister R, Ko M et al. Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature 2011 473 394-397.
24. Wu H, D'Alessio AC, Ito S, Wang Z, Cui K, Zhao K et al. Genome-wide analysis of 5-hydroxymethylcytosine distribution reveals its dual function in transcriptional regulation in mouse embryonic stem cells. Gene Dev 2011 25 679-684.
25. Hackett JA, Sengupta R, Zylicz JJ, Murakami K, Lee C, Down TA et al. Germline DNA demethylation dynamics and imprint erasure through 5-hydroxymethylcytosine. Science 2013 339 448-452.
26. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Masse A et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009 360 2289-2301.
27. Chou WC, Chou SC, Liu CY, Chen CY, Hou HA, Kuo YY et al. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood 2011 118 3803-3810.
28. Jankowska AM, Makishima H, Tiu RV, Szpurka H, Huang Y, Traina F et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation UTX, EZH2, and DNMT3A. Blood 2011 118 3932-3941.
29. Metzeler KH, Maharry K, Radmacher MD, Mrozek K, Margeson D, Becker H et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia a Cancer and Leukemia Group B study. J Clin Oncol 2011 29 1373-1381.
30. Li Z, Cai X, Cai CL, Wang J, Zhang W, Petersen BE et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 2011 118 4509-4518.
31. Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011 20 11-24.
32. Quivoron C, Couronne L, Della Valle V, Lopez CK, Plo I, Wagner-Ballon O et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 2011 20 25-38.
33. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010 18 553-567.
34. Abbas S, Lugthart S, Kavelaars FG, Schelen A, Koenders JE, Zeilemaker A et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia prevalence and prognostic value. Blood 2010 116 2122-2126.
35. Boissel N, Nibourel O, Renneville A, Gardin C, Reman O, Contentin N et al. Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia a study by the Acute Leukemia French Association group. J Clin Oncol 2010 28 3717-3723.
36. Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrozek K, Margeson D et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia a Cancer and Leukemia Group B study. J Clin Oncol 2010 28 2348-2355.
37. Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Kronke J, Bullinger L et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010 28 3636-3643.
38. Schnittger S, Haferlach C, Ulke M, Alpermann T, Kern W, Haferlach T. IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood 2010 116 5486-5496.
39. Green CL, Evans CM, Zhao L, Hills RK, Burnett AK, Linch DC et al. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood 2011 118 409-412.
40. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009 462 739-744.
41. Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG et al. Cancerassociated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 2010 207 339-344.
42. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012 483 474-478.
43. Chaturvedi A, Araujo Cruz MM, Jyotsana N, Sharma A, Yun H, Gorlich K et al. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood 2013 122 2877-2887.
44. Sasaki M, Knobbe CB, Munger JC, Lind EF, Brenner D, Brustle A et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 2012 488 656-659.
45. Janin M, Mylonas E, Saada V, Micol JB, Renneville A, Quivoron C et al. Serum 2-Hydroxyglutarate Production in IDH1-and IDH2-Mutated De Novo Acute Myeloid Leukemia A Study by the Acute Leukemia French Association Group. J Clin Oncol 2013 32 297-305.
46. Argiropoulos B, Humphries RK. Hox genes in hematopoiesis and leukemogenesis. Oncogene 2007 26 6766-6776.
47. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002 298 1039-1043.
48. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010 42 181-185.
49. Nikoloski G, Langemeijer SM, Kuiper RP, Knops R, Massop M, Tö nnissen ER et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 2010 42 665-667.
50. Pasqualucci L, Trifonov V, Fabbri G, Ma J, Rossi D, Chiarenza A et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 2011 43 830-837.
51. Kroeze LI, Nikoloski G, da Silva-Coelho P, van Hoogen P, Stevens-Linders E, Kuiper RP et al. Genetic defects in PRC2 components other than EZH2 are not common in myeloid malignancies. Blood 2012 119 1318-1319.
52. Ntziachristos P, Tsirigos A, Van Vlierberghe P, Nedjic J, Trimarchi T, Flaherty MS et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med 2012 18 298-301.
53. Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012 366 1079-1089.
54. Abdel-Wahab O, Pardanani A, Patel J, Wadleigh M, Lasho T, Heguy A et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 2011 25 1200-1202.
55. Abdel-Wahab O, Adli M, LaFave LM, Gao J, Hricik T, Shih AH et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer cell 2012 22 180-193.
56. Peng JC, Valouev A, Swigut T, Zhang J, Zhao Y, Sidow A et al. Jarid2/Jumonji coordinates control of PRC2 enzymatic activity and target gene occupancy in pluripotent cells. Cell 2009 139 1290-1302.
57. Puda A, Milosevic JD, Berg T, Klampfl T, Harutyunyan AS, Gisslinger B et al. Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. Am J hematol 2012 87 245-250.
58. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 2006 6 846-856.
59. Smith LL, Yeung J, Zeisig BB, Popov N, Huijbers I, Barnes J et al. Functional crosstalk between Bmi1 and MLL/Hoxa9 axis in establishment of normal hematopoietic and leukemic stem cells. Cell Stem Cell 2011 8 649-662.
60. Yuan J, Takeuchi M, Negishi M, Oguro H, Ichikawa H, Iwama A. Bmi1 is essential for leukemic reprogramming of myeloid progenitor cells. Leukemia 2011 25 1335-1343.
61. Xu F, Li X, Wu L, Zhang Q, Yang R, Yang Y et al. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes relation to adverse epigenetic alteration and poor prognostic scoring. Ann Hematol 2011 90 643-653.
62. Cales C, Roman-Trufero M, Pavon L, Serrano I, Melgar T, Endoh M et al. Inactivation of the polycomb group protein Ring1B unveils an antiproliferative role in hematopoietic cell expansion and cooperation with tumorigenesis associated with Ink4a deletion. Mol Cell Biol 2008 28 1018-1028.
63. Boukarabila H, Saurin AJ, Batsche E, Mossadegh N, van Lohuizen M, Otte AP et al. The PRC1 Polycomb group complex interacts with PLZF/RARA to mediate leukemic transformation. Gene Dev 2009 23 1195-1206.
64. Li G, Margueron R, Ku M, Chambon P, Bernstein BE, Reinberg D. Jarid2 and PRC2, partners in regulating gene expression. Genes Dev 2010 24 368-380.
65. Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006 439 871-874.
66. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia a Southwest Oncology Group/Eastern Co operative Oncology Group Study. Blood 2000 96 4075-4083.
67. Dohner K, Tobis K, Ulrich R, Frohling S, Benner A, Schlenk RF et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics a study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol 2002 20 3254-3261.
68. Balgobind BV, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA, Auvrignon A et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia results of an international retrospective study. Blood 2009 114 2489-2496.
69. Steudel C, Wermke M, Schaich M, Schakel U, Illmer T, Ehninger G et al. Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia. Genes Chromosomes Cancer 2003 37 237-251.
70. Whitman SP, Ruppert AS, Marcucci G, Mrozek K, Paschka P, Langer C et al. Longterm disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication a Cancer and Leukemia Group B study. Blood 2007 109 5164-5167.
71. Caligiuri MA, Schichman SA, Strout MP, Mrozek K, Baer MR, Frankel SR et al. Molecular rearrangement of the ALL-1 gene in acute myeloid leukemia without cytogenetic evidence of 11q23 chromosomal translocations. Cancer Res 1994 54 370-373.
72. Milne TA, Briggs SD, Brock HW, Martin ME, Gibbs D, Allis CD et al. MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell 2002 10 1107-1117.
73. Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006 442 818-822.
74. Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 2011 20 66-78.
75. Jo SY, Granowicz EM, Maillard I, Thomas D, Hess JL. Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation. Blood 2011 117 4759-4768.
76. Nguyen AT, Taranova O, He J, Zhang Y. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. Blood 2011 117 6912-6922.
77. Yokoyama A, Somervaille TC, Smith KS, Rozenblatt-Rosen O, Meyerson M, Cleary ML. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 2005 123 207-218.
78. Yokoyama A, Cleary ML. Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell 2008 14 36-46.
79. Caslini C, Yang Z, El-Osta M, Milne TA, Slany RK, Hess JL. Interaction of MLL amino terminal sequences with menin is required for transformation. Cancer Res 2007 67 7275-7283.
80. Grembecka J, He S, Shi A, Purohit T, Muntean AG, Sorenson RJ et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat Chem Biol 2012 8 277-284.
81. Mereau H, De Rijck J, Cermakova K, Kutz A, Juge S, Demeulemeester J et al. Impairing MLL-fusion gene-mediated transformation by dissecting critical interactions with the lens epithelium-derived growth factor (LEDGF/p75). Leukemia 2013 27 1245-1253.
82. Cerveira N, Correia C, Doria S, Bizarro S, Rocha P, Gomes P et al. Frequency of NUP98-NSD1 fusion transcript in childhood acute myeloid leukaemia. Leukemia 2003 17 2244-2247.
83. Wang GG, Cai L, Pasillas MP, Kamps MP. NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nat Cell Biol 2007 9 804-812.
84. Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, Pratcorona M, Abbas S, Kuipers JE et al. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood 2011 118 3645-3656.
85. Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004 119 941-953.
86. He J, Nguyen AT, Zhang Y. KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia. Blood 2011 117 3869-3880.
87. de Rooij JD, Hollink IH, Arentsen-Peters ST, van Galen JF, Berna Beverloo H, Baruchel A et al. NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern. Leukemia 2013 27 2280-2288.
88. Gruber TA, Larson Gedman A, Zhang J, Koss CS, Marada S, Ta HQ et al. An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. Cancer Cell 2012 22 683-697.
89. Wang GG, Song J, Wang Z, Dormann HL, Casadio F, Li H et al. Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger. Nature 2009 459 847-851.
90. Agger K, Cloos PA, Christensen J, Pasini D, Rose S, Rappsilber J et al. UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature 2007 449 731-734.
91. van Haaften G, Dalgliesh GL, Davies H, Chen L, Bignell G, Greenman C et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet 2009 41 521-523.
92. Mar BG, Bullinger L, Basu E, Schlis K, Silverman LB, Dohner K et al. Sequencing histone-modifying enzymes identifies UTX mutations in acute lymphoblastic leukemia. Leukemia 2012 26 1881-1883.
93. Jansson M, Durant ST, Cho EC, Sheahan S, Edelmann M, Kessler B et al. Arginine methylation regulates the p53 response. Nat Cell Biol 2008 10 1431-1439.
94. Zhao Q, Rank G, Tan YT, Li H, Moritz RL, Simpson RJ et al. PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing. Nat Struct Mol Biol 2009 16 304-311.
95. Liu F, Zhao X, Perna F, Wang L, Koppikar P, Abdel-Wahab O et al. JAK2V617Fmediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell 2011 19 283-294.
96. Vu LP, Perna F, Wang L, Voza F, Figueroa ME, Tempst P et al. PRMT4 blocks myeloid differentiation by assembling a Methyl-RUNX1-dependent repressor complex. Cell Rep 2013 5 1625-1638.
97. Cheung N, Chan LC, Thompson A, Cleary ML, So CW. Protein argininemethyltransferase-dependent oncogenesis. Nat Cell Biol 2007 9 1208-1215.
98. Guccione E, Bassi C, Casadio F, Martinato F, Cesaroni M, Schuchlautz H et al. Methylation of histone H3R2 by PRMT6 and H3K4 by an MLL complex are mutually exclusive. Nature 2007 449 933-937.
99. Mullighan CG, Zhang J, Kasper LH, Lerach S, Payne-Turner D, Phillips LA et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 2011 471 235-239.
100. Inthal A, Zeitlhofer P, Zeginigg M, Morak M, Grausenburger R, Fronkova E et al. CREBBP HAT domain mutations prevail in relapse cases of high hyperdiploid childhood acute lymphoblastic leukemia. Leukemia 2012 26 1797-1803.
101. Voss AK, Collin C, Dixon MP, Thomas T. Moz and retinoic acid coordinately regulate H3K9 acetylation, Hox gene expression, and segment identity. Dev Cell 2009 17 674-686.
102. Katsumoto T, Aikawa Y, Iwama A, Ueda S, Ichikawa H, Ochiya T et al. MOZ is essential for maintenance of hematopoietic stem cells. Gene Dev 2006 20 1321-1330.
103. Perez-Campo FM, Borrow J, Kouskoff V, Lacaud G. The histone acetyl transferase activity of monocytic leukemia zinc finger is critical for the proliferation of hematopoietic precursors. Blood 2009 113 4866-4874.
104. Chaffanet M, Gressin L, Preudhomme C, Soenen-Cornu V, Birnbaum D, Pebusque MJ. MOZ is fused to p300 in an acute monocytic leukemia with t(822). Genes Chromosomes Cancer 2000 28 138-144.
105. Deguchi K, Ayton PM, Carapeti M, Kutok JL, Snyder CS, Williams IR et al. MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP. Cancer Cell 2003 3 259-271.
106. Crowley JA, Wang Y, Rapoport AP, Ning Y. Detection of MOZ-CBP fusion in acute myeloid leukemia with 816 translocation. Leukemia 2005 19 2344-2345.
107. Sun Y, Jiang X, Xu Y, Ayrapetov MK, Moreau LA, Whetstine JR et al. Histone H3 methylation links DNA damage detection to activation of the tumour suppressor Tip60. Nat Cell Biol 2009 11 1376-1382.
108. Nordentoft I, Jorgensen P. The acetyltransferase 60 kDa trans-acting regulatory protein of HIV type 1-interacting protein (Tip60) interacts with the translocation E26 transforming-specific leukaemia gene (TEL) and functions as a transcriptional co-repressor. Biochem J 2003 374(Pt 1) 165-173.
109. Tan J, Jones M, Koseki H, Nakayama M, Muntean AG, Maillard I et al. CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis. Cancer Cell 2011 20 563-575.
110. Neff T, Sinha AU, Kluk MJ, Zhu N, Khattab MH, Stein L et al. Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Proc Natl Acad SciUSA 2012 109 5028-5033.
111. Shi A, Murai MJ, He S, Lund G, Hartley T, Purohit T et al. Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia. Blood 2012 120 4461-4469.
112. Thiel AT, Feng Z, Pant DK, Chodosh LA, Hua X. The trithorax protein partner menin acts in tandem with EZH2 to suppress C/EBPalpha and differentiation in MLL-AF9 leukemia. Haematologica 2013 98 918-927.
113. Tanaka S, Miyagi S, Sashida G, Chiba T, Yuan J, Mochizuki-Kashio M et al. Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. Blood 2012 120 1107-1117.
114. Villa R, Pasini D, Gutierrez A, Morey L, Occhionorelli M, Vire E et al. Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer Cell 2007 11 513-525.
115. Okada Y, Feng Q, Lin Y, Jiang Q, Li Y, Coffield VM et al. hDOT1L links histone methylation to leukemogenesis. Cell 2005 121 167-178.
116. Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 2011 20 53-65.
117. Daigle SR, Olhava EJ, Therkelsen CA, Basavapathruni A, Jin L, Boriack-Sjodin PA et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 2013 122 1017-1025.
118. Yu W, Chory EJ, Wernimont AK, Tempel W, Scopton A, Federation A et al. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat Commun 2012 3 1288.
119. Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012 150 264-278.
120. Geiman TM, Sankpal UT, Robertson AK, Chen Y, Mazumdar M, Heale JT et al. Isolation and characterization of a novel DNA methyltransferase complex linking DNMT3B with components of the mitotic chromosome condensation machinery. Nucleic Acid Res 2004 32 2716-2729.
121. Quesada V, Conde L, Villamor N, Ordonez GR, Jares P, Bassaganyas L et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 2012 44 47-52.
122. Wang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, Stevenson K et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011 365 2497-2506.
123. Mian SA, Smith AE, Kulasekararaj AG, Kizilors A, Mohamedali AM, Lea NC et al. Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome. Haematologica 2013 98 1058-1066.
124. Busque L, Patel JP, Figueroa ME, Vasanthakumar A, Provost S, Hamilou Z et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet 2012 44 1179-1181.
125. Jan M, Snyder TM, Corces-Zimmerman MR, Vyas P, Weissman IL, Quake SR et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med 2012 4 149ra118.
126. Boultwood J, Perry J, Pellagatti A, Fernandez-Mercado M, Fernandez-Santamaria C, Calasanz MJ et al. Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia 2010 24 1062-1065.
127. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010 42 722-726.
128. Grossmann V, Kohlmann A, Eder C, Haferlach C, Kern W, Cross NC et al. Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in 480% of patients with TET2 and EZH2 being of high prognostic relevance. Leukemia 2011 25 877-879.
129. Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013 340 626-630.
130. Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, Hansen E et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 2013 340 622-626.
131. Schenk T, Chen WC, Gollner S, Howell L, Jin L, Hebestreit K et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med 2012 18 605-611.
132. Konze KD, Ma A, Li F, Barsyte-Lovejoy D, Parton T, Macnevin CJ et al. An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1. ACS Chem Biol 2013 8 1324-1334.
133. Knutson SK, Wigle TJ, Warholic NM, Sneeringer CJ, Allain CJ, Klaus CR et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 2012 8 890-896.
134. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012 492 108-112.
135. Kim W, Bird GH, Neff T, Guo G, Kerenyi MA, Walensky LD et al. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nat Chem Biol 2013 9 643-650.
136. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011 478 529-533.
137. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011 478 524-528.
138. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O et al. Selective inhibition of BET bromodomains. Nature 2010 468 1067-1073.
139. Ott CJ, Kopp N, Bird L, Paranal RM, Qi J, Bowman T et al. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood 2012 120 2843-2852.
140. Herold JM, Wigle TJ, Norris JL, Lam R, Korboukh VK, Gao C et al. Small-molecule ligands of methyl-lysine binding proteins. J Med Chem 2011 54 2504-2511.
141. Garcia-Manero G, Gore SD, Cogle C, Ward R, Shi T, Macbeth KJ et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol 2011 29 2521-2527.
142. Negrotto S, Ng KP, Jankowska AM, Bodo J, Gopalan B, Guinta K et al. CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors. Leukemia 2012 26 244-254.
143. Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 2012 21 430-446.
144. Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 2010 28 605-613.
145. Fandy TE, Herman JG, Kerns P, Jiemjit A, Sugar EA, Choi SH et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 2009 114 2764-2773.
146. Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad SciUSA 2010 107 7473-7478.
147. Klco JM, Spencer DH, Lamprecht TL, Sarkaria SM, Wylie T, Magrini V et al. Genomic impact of transient low-dose decitabine treatment on primary AML cells. Blood 2013 121 1633-1643.
148. Rao R, Fiskus W, Yang Y, Lee P, Joshi R, Fernandez P et al. HDAC6 inhibition enhances 17-AAG-mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood 2008 112 1886-1893.
149. Yu C, Rahmani M, Conrad D, Subler M, Dent P, Grant S. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl\+ cells sensitive and resistant to STI571. Blood 2003 102 3765-3774.
150. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011 146 904-917.
151. Picaud S, Da Costa D, Thanasopoulou A, Filippakopoulos P, Fish PV, Philpott M et al. PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains. Cancer Res 2013 73 3336-3346.
152. Rubnitz JE, Wichlan D, Devidas M, Shuster J, Linda SB, Kurtzberg J et al. Prospective analysis of TEL gene rearrangements in childhood acute lymphoblastic leukemia a Children's Oncology Group study. J Clin Oncol 2008 26 2186-2191.
153. Bhojwani D, Pei D, Sandlund JT, Jeha S, Ribeiro RC, Rubnitz JE et al. ETV6-RUNX1-positive childhood acute lymphoblastic leukemia improved outcome with contemporary therapy. Leukemia 2012 26 265-270.
154. Gang EJ, Hsieh YT, Pham J, Zhao Y, Nguyen C, Huantes S et al. Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia. Oncogene 2014 33 2169-2178.
155. Gao XN, Lin J, Ning QY, Gao L, Yao YS, Zhou JH et al. A histone acetyltransferase p300 inhibitor C646 induces cell cycle arrest and apoptosis selectively in AML1-ETO-positive AML cells. PLoS One 2013 8 e55481.
156. Falk H, Connor T, Yang H, Loft KJ, Alcindor JL, Nikolakopoulos G et al. An efficient high-throughput screening method for MYST family acetyltransferases, a new class of epigenetic drug targets. J Biomol Screening 2011 16 1196-1205.
157. Harris WJ, Huang X, Lynch JT, Spencer GJ, Hitchin JR, Li Y et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 2012 21 473-487.
158. Kruidenier L, Chung CW, Cheng Z, Liddle J, Che K, Joberty G et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 2012 488 404-408.
159. Sayegh J, Cao J, Zou MR, Morales A, Blair LP, Norcia M et al. Identification of small molecule inhibitors of Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen. J Biol Chem 2013 288 9408-9417.
160. Vedadi M, Barsyte-Lovejoy D, Liu F, Rival-Gervier S, Allali-Hassani A, Labrie V et al. A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat Chem Biol 2011 7 566-574.
161. Kubicek S, O'Sullivan RJ, August EM, Hickey ER, Zhang Q, Teodoro ML et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell 2007 25 473-481.
162. Wan H, Huynh T, Pang S, Geng J, Vaccaro W, Poss MA et al. Benzo[d]imidazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1)-Hit to Lead studies. Bio-org Med Chem Lett 2009 19 5063-5066.
163. Sack JS, Thieffine S, Bandiera T, Fasolini M, Duke GJ, Jayaraman L et al. Structural basis for CARM1 inhibition by indole and pyrazole inhibitors. Biochem J 2011 436 331-339.
164. Shia WJ, Okumura AJ, Yan M, Sarkeshik A, Lo MC, Matsuura S et al. PRMT1 interacts with AML1-ETO to promote its transcriptional activation and progenitor cell proliferative potential. Blood 2012 119 4953-4962.